Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2011

Open Access 01-12-2011 | Research

Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity

Authors: Shawn A Ritchie, Dushmanthi Jayasinghe, Gerald F Davies, Pearson Ahiahonu, Hong Ma, Dayan B Goodenowe

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Login to get access

Abstract

Background

Circulating levels of novel long-chain hydroxy fatty acids (called GTAs) were recently discovered in the serum of healthy subjects which were shown to be reduced in subjects with colorectal cancer (CRC), independent of tumor burden or disease stage. The levels of GTAs were subsequently observed to exhibit an inverse association with age in the general population. The current work investigates the biological activity of these fatty acids by evaluating the effects of enriched human serum extracts on cell growth and inflammation.

Methods

GTAs were extracted from commercially available bulk human serum and then chromatographically separated into enriched (GTA-positive) and depleted (GTA-negative) fractions. SW620, MCF7 and LPS stimulated RAW264.7 cells were treated with various concentrations of the GTA-positive and GTA-negative extracts, and the effects on cell growth and inflammation determined.

Results

Enriched fractions resulted in poly-ADP ribose polymerase (PARP) cleavage, suppression of NFκB, induction of IκBα, and reduction in NOS2 mRNA transcript levels. In RAW264.7 mouse macrophage cells, incubation with enriched fractions prior to treatment with LPS blocked the induction of several pro-inflammatory markers including nitric oxide, TNFα, IL-1β, NOS2 and COX2.

Conclusions

Our results show that human serum extracts enriched with endogenous long-chain hydroxy fatty acids possess anti-inflammatory and anti-proliferative activity. These findings support a hypothesis that the reduction of these metabolites with age may result in a compromised ability to defend against uncontrolled cell growth and inflammation, and could therefore represent a significant risk for the development of CRC.
Appendix
Available only for authorised users
Literature
1.
Schwab JM, Chiang N, Arita M, Serhan CN: Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007, 447: 869-874. 10.1038/nature05877.PubMedCentralCrossRefPubMed
2.
Serhan CN: Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Anesthesiol Clin. 2006, 24: 341-364. 10.1016/j.atc.2006.01.003.CrossRefPubMed
3.
Schwab JM, Serhan CN: Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol. 2006, 6: 414-420. 10.1016/j.coph.2006.02.006.CrossRefPubMed
4.
Hong S, Lee HJ, Kim SJ, Hahm KB: Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling. World J Gastroenterol. 2010, 16: 2080-2093. 10.3748/wjg.v16.i17.2080.PubMedCentralCrossRefPubMed
5.
Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT: Cancer and inflammation: promise for biologic therapy. J Immunother. 2010, 33: 335-351. 10.1097/CJI.0b013e3181d32e74.PubMedCentralCrossRefPubMed
6.
Senthil K, Aranganathan S, Nalini N: Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta. 2004, 339: 27-32. 10.1016/j.cccn.2003.08.017.CrossRefPubMed
7.
Itzkowitz SH, Yio X: Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004, 287: G7-17. 10.1152/ajpgi.00079.2004.CrossRefPubMed
8.
Das UN: Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer's disease--but how and why?. Prostaglandins Leukot Essent Fatty Acids. 2008, 78: 11-19. 10.1016/j.plefa.2007.10.006.CrossRefPubMed
9.
Spiteller G: Peroxyl radicals: inductors of neurodegenerative and other inflammatory diseases. Their origin and how they transform cholesterol, phospholipids, plasmalogens, polyunsaturated fatty acids, sugars, and proteins into deleterious products. Free Radic Biol Med. 2006, 41: 362-387. 10.1016/j.freeradbiomed.2006.03.013.CrossRefPubMed
10.
11.
Sumariwalla PF, Palmer CD, Pickford LB, Feldmann M, Foxwell BM, Brennan FM: Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717. Rheumatology (Oxford). 2009, 48: 32-38.CrossRef
12.
Simmonds RE, Foxwell BM: Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford). 2008, 47: 584-590. 10.1093/rheumatology/kem298.CrossRef
13.
Jin JQ, Li CQ, He LC: Down-regulatory effect of usnic acid on nuclear factor-kappaB-dependent tumor necrosis factor-alpha and inducible nitric oxide synthase expression in lipopolysaccharide-stimulated macrophages RAW 264.7. Phytother Res. 2008, 22: 1605-1609. 10.1002/ptr.2531.CrossRefPubMed
14.
Yun KJ, Koh DJ, Kim SH, Park SJ, Ryu JH, Kim DG, Lee JY, Lee KT: Anti-inflammatory effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygase-2, and proinflammatory cytokines expressions via nuclear factor-kappaB inactivation. J Agric Food Chem. 2008, 56: 10265-10272. 10.1021/jf802095g.CrossRefPubMed
15.
Nakanishi Y, Kamijo R, Takizawa K, Hatori M, Nagumo M: Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. Eur J Cancer. 2001, 37: 1570-1578. 10.1016/S0959-8049(01)00160-5.CrossRefPubMed
16.
Jobin C, Morteau O, Han DS, Balfour Sartor R: Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology. 1998, 95: 537-543. 10.1046/j.1365-2567.1998.00646.x.PubMedCentralCrossRefPubMed
17.
Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010, 8: 13-10.1186/1741-7015-8-13.PubMedCentralCrossRefPubMed
18.
Ritchie SA, Heath D, Yamazaki Y, Grimmalt B, Kavianpour A, Krenitsky K, Elshoni H, Takemasa I, Miyake M, Sekimoto M, Monden M, Tomonaga T, Matsubara H, Sogawa K, Matsushita K, Nomura F, Goodenowe DB: Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age. BMC Gastroenterol. 2010, 10: 140-10.1186/1471-230X-10-140.PubMedCentralCrossRefPubMed
19.
Davies GF, Roesler WJ, Juurlink BH, Harkness TA: Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk Lymphoma. 2005, 46: 1199-1206. 10.1080/10428190500102555.CrossRefPubMed
20.
Serhan CN: Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J Periodontol. 2008, 79: 1520-1526. 10.1902/jop.2008.080231.CrossRefPubMed
21.
Seki H, Tani Y, Arita M: Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat. 2009, 89: 126-130. 10.1016/j.prostaglandins.2009.03.002.CrossRefPubMed
22.
O'Connor PM, Lapointe TK, Beck PL, Buret AG: Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis. 2010, 16: 1411-1420.CrossRefPubMed
23.
Chaitanya GV, Babu PP: Differential PARP cleavage: an indication of heterogeneous forms of cell death and involvement of multiple proteases in the infarct of focal cerebral ischemia in rat. Cell Mol Neurobiol. 2009, 29: 563-573. 10.1007/s10571-009-9348-8.CrossRefPubMed
24.
Toit-Kohn JL, Louw L, Engelbrecht AM: Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways. J Nutr Biochem. 2009, 20: 106-114. 10.1016/j.jnutbio.2007.12.005.CrossRefPubMed
25.
Narayanan BA, Narayanan NK, Reddy BS: Docosahexaenoic acid regulated genes and transcription factors inducing apoptosis in human colon cancer cells. Int J Oncol. 2001, 19: 1255-1262.PubMed
26.
Engelbrecht AM, Toit-Kohn JL, Ellis B, Thomas M, Nell T, Smith R: Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model. Apoptosis. 2008, 13: 1368-1377. 10.1007/s10495-008-0260-3.CrossRefPubMed
27.
Grossmann ME, Mizuno NK, Schuster T, Cleary MP: Punicic acid is an omega-5 fatty acid capable of inhibiting breast cancer proliferation. Int J Oncol. 2010, 36: 421-426.PubMed
28.
Chapkin RS, Seo J, McMurray DN, Lupton JR: Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine. Chem Phys Lipids. 2008, 153: 14-23. 10.1016/j.chemphyslip.2008.02.011.PubMedCentralCrossRefPubMed
29.
Kolar SS, Barhoumi R, Lupton JR, Chapkin RS: Docosahexaenoic acid and butyrate synergistically induce colonocyte apoptosis by enhancing mitochondrial Ca2+ accumulation. Cancer Res. 2007, 67: 5561-5568. 10.1158/0008-5472.CAN-06-4716.CrossRefPubMed
30.
Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ: Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006, 12: 4662-4670. 10.1158/1078-0432.CCR-06-0459.PubMedCentralCrossRefPubMed
31.
Rose DP, Connolly JM: Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int J Oncol. 1999, 15: 1011-1015.PubMed
32.
Reddy BS, Maruyama H: Effect of dietary fish oil on azoxymethane-induced colon carcinogenesis in male F344 rats. Cancer Res. 1986, 46: 3367-3370.PubMed
33.
Reddy BS, Burill C, Rigotty J: Effect of diets high in omega-3 and omega-6 fatty acids on initiation and postinitiation stages of colon carcinogenesis. Cancer Res. 1991, 51: 487-491.PubMed
34.
Wendel M, Heller AR: Anticancer actions of omega-3 fatty acids--current state and future perspectives. Anticancer Agents Med Chem. 2009, 9: 457-470.CrossRefPubMed
35.
Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SH, Schmidt-Ullrich R, Steinhoff U: Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest. 2006, 116: 3195-3203. 10.1172/JCI28804.PubMedCentralCrossRefPubMed
36.
Gyrd-Hansen M, Meier P: IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer. 2010, 10: 561-574. 10.1038/nrc2889.CrossRefPubMed
37.
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004, 118: 285-296. 10.1016/j.cell.2004.07.013.CrossRefPubMed
38.
Varfolomeev E, Vucic D: (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle. 2008, 7: 1511-1521. 10.4161/cc.7.11.5959.CrossRefPubMed
39.
Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D: IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007, 131: 669-681. 10.1016/j.cell.2007.10.030.CrossRefPubMed
40.
Vassiliou EK, Kesler OM, Tadros JH, Ganea D: Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells. J Immunol. 2008, 181: 4534-4544.CrossRefPubMed
41.
Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN: Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005, 201: 713-722. 10.1084/jem.20042031.PubMedCentralCrossRefPubMed
42.
Harpaz N, Polydorides AD: Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, and pathogenesis. Arch Pathol Lab Med. 2010, 134: 876-895.PubMed
43.
44.
Spehlmann ME, Eckmann L: Nuclear factor-kappa B in intestinal protection and destruction. Curr Opin Gastroenterol. 2009, 25: 92-99. 10.1097/MOG.0b013e328324f857.CrossRefPubMed
45.
Karrasch T, Jobin C: NF-kappaB and the intestine: friend or foe?. Inflamm Bowel Dis. 2008, 14: 114-124. 10.1002/ibd.20243.CrossRefPubMed
46.
Gadjeva M, Wang Y, Horwitz BH: NF-kappaB p50 and p65 subunits control intestinal homeostasis. Eur J Immunol. 2007, 37: 2509-2517. 10.1002/eji.200737186.CrossRefPubMed
47.
48.
Ellis RD, Goodlad JR, Limb GA, Powell JJ, Thompson RP, Punchard NA: Activation of nuclear factor kappa B in Crohn's disease. Inflamm Res. 1998, 47: 440-445. 10.1007/s000110050358.CrossRefPubMed
49.
Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J, Gross V: Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998, 115: 357-369. 10.1016/S0016-5085(98)70202-1.CrossRefPubMed
50.
Abdullah M, Sudoyo AW, Pranowo BS, Rini D, Sutrisna B, Rani AA: Expression of NF-kappaB and COX-2 in young versus older patients with sporadic colorectal cancer. Acta Med Indones. 2009, 41: 70-74.PubMed
51.
Sun XF, Zhang H: NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol. 2007, 22: 1387-1398.PubMed
52.
Charalambous MP, Lightfoot T, Speirs V, Horgan K, Gooderham NJ: Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. Br J Cancer. 2009, 101: 106-115. 10.1038/sj.bjc.6605120.PubMedCentralCrossRefPubMed
53.
Xiao ZQ, Majumdar AP: Induction of transcriptional activity of AP-1 and NF-kappaB in the gastric mucosa during aging. Am J Physiol Gastrointest Liver Physiol. 2000, 278: G855-865.PubMed
54.
Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, Lee WH, Fitzgerald KA, Hwang DH: Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem. 2004, 279: 16971-16979. 10.1074/jbc.M312990200.CrossRefPubMed
55.
Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, Hwang DH: Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003, 44: 479-486. 10.1194/jlr.M200361-JLR200.CrossRefPubMed
56.
Lee JY, Sohn KH, Rhee SH, Hwang D: Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001, 276: 16683-16689. 10.1074/jbc.M011695200.CrossRefPubMed
57.
Kirschning CJ, Schumann RR: TLR2: cellular sensor for microbial and endogenous molecular patterns. Curr Top Microbiol Immunol. 2002, 270: 121-144.PubMed
58.
Kriete A, Mayo KL: Atypical pathways of NF-kappaB activation and aging. Exp Gerontol. 2009, 44: 250-255. 10.1016/j.exger.2008.12.005.CrossRefPubMed
59.
Adler AS, Kawahara TL, Segal E, Chang HY: Reversal of aging by NFkappaB blockade. Cell Cycle. 2008, 7: 556-559. 10.4161/cc.7.5.5490.CrossRefPubMed
60.
Donato AJ, Black AD, Jablonski KL, Gano LB, Seals DR: Aging is associated with greater nuclear NF kappa B, reduced I kappa B alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell. 2008, 7: 805-812. 10.1111/j.1474-9726.2008.00438.x.PubMedCentralCrossRefPubMed
61.
Giardina C, Hubbard AK: Growing old with nuclear factor-kappaB. Cell Stress Chaperones. 2002, 7: 207-212. 10.1379/1466-1268(2002)007<0207:GOWNFB>2.0.CO;2.PubMedCentralCrossRefPubMed
62.
Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T: Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev. 2008, 7: 83-105. 10.1016/j.arr.2007.09.002.CrossRefPubMed
63.
Salminen A, Ojala J, Huuskonen J, Kauppinen A, Suuronen T, Kaarniranta K: Interaction of aging-associated signaling cascades: inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell Mol Life Sci. 2008, 65: 1049-1058. 10.1007/s00018-008-7461-3.CrossRefPubMed
64.
Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E, Chang HY: Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev. 2007, 21: 3244-3257. 10.1101/gad.1588507.PubMedCentralCrossRefPubMed
65.
Enck P, Zimmermann K, Rusch K, Schwiertz A, Klosterhalfen S, Frick JS: The effects of ageing on the colonic bacterial microflora in adults. Z Gastroenterol. 2009, 47: 653-658. 10.1055/s-0028-1109055.CrossRefPubMed
66.
He F, Ouwehand AC, Isolauri E, Hosoda M, Benno Y, Salminen S: Differences in composition and mucosal adhesion of bifidobacteria isolated from healthy adults and healthy seniors. Curr Microbiol. 2001, 43: 351-354. 10.1007/s002840010315.CrossRefPubMed
67.
Hopkins MJ, Sharp R, Macfarlane GT: Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut. 2001, 48: 198-205. 10.1136/gut.48.2.198.PubMedCentralCrossRefPubMed
68.
Saunier K, Dore J: Gastrointestinal tract and the elderly: functional foods, gut microflora and healthy ageing. Dig Liver Dis. 2002, 34 (Suppl 2): S19-24.CrossRefPubMed
69.
Musso G, Gambino R, Cassader M: Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?. Diabetes Care. 2010, 33: 2277-2284. 10.2337/dc10-0556.PubMedCentralCrossRefPubMed
70.
Fava F, Lovegrove JA, Gitau R, Jackson KG, Tuohy KM: The gut microbiota and lipid metabolism: implications for human health and coronary heart disease. Curr Med Chem. 2006, 13: 3005-3021. 10.2174/092986706778521814.CrossRefPubMed
71.
Petruzzelli M, Moschetta A: Intestinal ecology in the metabolic syndrome. Cell Metab. 2010, 11: 345-346. 10.1016/j.cmet.2010.04.012.CrossRefPubMed
72.
Gunter MJ, Leitzmann MF: Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem. 2006, 17: 145-156. 10.1016/j.jnutbio.2005.06.011.CrossRefPubMed
73.
Ehrmann-Josko A, Sieminska J, Gornicka B, Ziarkiewicz-Wroblewska B, Ziolkowski B, Muszynski J: Impaired glucose metabolism in colorectal cancer. Scand J Gastroenterol. 2006, 41: 1079-1086. 10.1080/00365520600587444.CrossRefPubMed
74.
Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL: Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol. 2009, 15: 5141-5148. 10.3748/wjg.15.5141.PubMedCentralCrossRefPubMed
75.
Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ: Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003, 12: 412-418.PubMed
76.
Kumar M, Kumar A, Nagpal R, Mohania D, Behare P, Verma V, Kumar P, Poddar D, Aggarwal PK, Henry CJ, Jain S, Yadav H: Cancer-preventing attributes of probiotics: an update. Int J Food Sci Nutr. 2010, 61: 473-496. 10.3109/09637480903455971.CrossRefPubMed
77.
Pufulete M: Intake of dairy products and risk of colorectal neoplasia. Nutr Res Rev. 2008, 21: 56-67.CrossRefPubMed
78.
Saikali J, Picard C, Freitas M, Holt P: Fermented milks, probiotic cultures, and colon cancer. Nutr Cancer. 2004, 49: 14-24. 10.1207/s15327914nc4901_3.CrossRefPubMed
Metadata
Title
Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity
Authors
Shawn A Ritchie
Dushmanthi Jayasinghe
Gerald F Davies
Pearson Ahiahonu
Hong Ma
Dayan B Goodenowe
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-30-59

Other articles of this Issue 1/2011

Journal of Experimental & Clinical Cancer Research 1/2011 Go to the issue

Research

miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level

Research

A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro

Research

RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study

Research

The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma

Research

Alcohol promotes breast cancer cell invasion by regulating the Nm23-ITGA5 pathway

Research

Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting Clusterin improves response to paclitaxel
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits